Real-world Effectiveness of Glecaprevir/Pibrentasvir (GLE/PIB) for Chronic Hepatitis C Infection: Evidence From a German Single-center Cohort Study
| Author | Claudia Beisel | en |
| Author | Marissa Herrmann | en |
| Author | Felix Piecha | en |
| Author | Sibylle Lampalzer | en |
| Author | Gustav Buescher | en |
| Author | Sven Pischke | en |
| Author | Julian Schulze zur Wiesch | en |
| Issued Date | 2021-01-31 | en |
| Abstract | Background: Glecaprevir/pibrentasvir (GLE/PIB) is the latest approved pan-genotypic direct-acting antiviral agent (DAA) for the treatment of chronic hepatitis C virus (HCV) infection. However, real-world data of GLE/PIB in European patient cohorts are limited. Methods: A single-center cohort of 100 unselected HCV patients seen at the Outpatient Clinic of the University Medical Center Hamburg-Eppendorf from October 2017 until September 2019 was retrospectively analyzed by chart review with a special focus on demographic clinical and virologic aspects as well as treatment compliance outcome. Results: A total of 99 patients with chronic HCV infection (genotype (GT) 1 - 6), who started antiviral treatment with GLE/PIB, were included. Treatment duration lasted from 4 to 16 weeks. The primary endpoint was a sustained virological response at week 12 (SVR12) after the end of treatment (EoT). Only three patients (3/100; 3%) were diagnosed with liver cirrhosis by non-invasive measures. Ten patients (10/100; 10%) were pre-treated with Interferon (IFN) containing regiments. Most patients received 8 weeks of treatment (96/100; 96%). One patient discontinued treatment after four weeks due to poor compliance (1/100; 1%). A high number of patients were lost to follow-up (22/100; 22%). All patients who were regularly seen to follow-up visits (76/100; 76%) achieved SVR12 (76/76; 100%). Virological relapse occurred in none of the patients. Adverse events (AEs) were rarely reported (4 patients) (4/100; 4%), and none of these patients discontinued treatment. Conclusions: This study demonstrated that initial and re-treatment with GLE/PIB were effective and safe in a German cohort with chronic HCV infection in real-life settings, regardless of GT. | en |
| DOI | https://doi.org/10.5812/hepatmon.110077 | en |
| Keyword | Real-life Data | en |
| Keyword | Chronic Hepatitis C Virus (HCV) Infection | en |
| Keyword | Direct Antiviral Agents (DAA) | en |
| Keyword | Glecaprevir/Pibrentasvir (GLE/PIB) | en |
| Publisher | Brieflands | en |
| Title | Real-world Effectiveness of Glecaprevir/Pibrentasvir (GLE/PIB) for Chronic Hepatitis C Infection: Evidence From a German Single-center Cohort Study | en |
| Type | Research Article | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- hepatmon-21-1-110077.pdf
- Size:
- 129.85 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF